Glow Plus Protocol: GHK-Cu, BPC-157 & TB-500 for Skin
Glow peptides are a name used by patients and clinicians for a specific two or three-peptide compounded preparation.
Some pharmacies prepare a 70 mg total version with different ratios. The 10/10/50 split is a common clinical practice. Limitless Alternative Medicine offers a 5 mg BPC-157, 5mg GHK-Cu formulation. GHK-Cu has the longest research history of the three components and has been studied at a wider range of concentrations, which is part of the rationale for its higher relative amount. The clinically appropriate ratio for any individual patient is determined by the prescribing physician.
Each peptide has been studied for distinct biological actions. BPC-157 has a substantial body of preclinical research focused on gastrointestinal and other visceral organ injury models, including the stomach, intestine, liver, and pancreas. TB-500 has been studied for its role in cell migration. GHK-Cu activates copper-dependent enzymes involved in collagen crosslinking. The rationale for combining them is that they target different mechanisms. Whether the combination produces additive clinical benefit beyond any single peptide has not been established in controlled human trials.
Clinical interest in glow preparations comes mainly from research on the individual peptides, much of it preclinical, with limited human data. The exact combination has not been tested in large clinical trials. This is a research summary, not a treatment recommendation, and these peptides are not FDA-approved for the indications discussed here.
A 15-amino-acid sequence originally isolated from a protein found in mammalian gastric juice. Research suggests it modulates the nitric oxide pathway, upregulates growth factor receptors, and promotes new blood vessel formation in damaged tissue.
Animal studies have investigated its role in tendon-to-bone healing, ligament repair, gastric ulcer healing, and protection of the intestinal lining against NSAID-induced injury. The angiogenesis findings are part of the research interest in stacked protocols, because vascular supply is a rate-limiting factor in soft tissue healing.
A separate area of research interest involves digestive symptoms. Some patients in clinical observation report changes in gastrointestinal symptoms during BPC-157 protocols, particularly those with a history of NSAID use or recent antibiotic courses. Controlled human data in this area remains limited. PubMed
A synthetic fragment of Thymosin Beta-4, a protein expressed in nearly every cell type in the body. Research has focused on its role in binding actin, the cytoskeletal protein that allows cells to migrate.
In tissue repair, repair cells must travel from surrounding tissue to the injury site. TB-500 has been studied for its role in this migration process and for its effects on scar tissue formation. Research applications include corneal wound healing, cardiac tissue, and musculoskeletal repair. Sosne, Qiu, Wheater
A three-amino-acid peptide (glycine, histidine, lysine) bound to a copper ion. The copper is a required cofactor for lysyl oxidase, the enzyme that crosslinks collagen and elastin into structurally organized tissue.
GHK-Cu has been studied since the 1970s, making it the most extensively researched peptide in this category. Research has investigated its role in tissue remodeling gene expression, inflammatory gene expression, and dermal fibroblast activity. It appears in cosmetic dermatology research as well as wound healing literature.
This is the component that distinguishes glow preparations from single-peptide protocols focused purely on injury recovery. It is also the component with the most established human research history.
"BPC-157 research is about getting repair started — new blood vessels, growth signals, raw tissue response. GHK-Cu research is about the quality of what gets built: collagen structure, elastin, the architecture of healthy skin and tissue."
Each pairing within glow preparations has some research literature behind it. The three-way combination has less.
The case for combining these peptides comes largely from individual-peptide research and clinical observation, not from head-to-head trials comparing the combination to single peptides or to placebo. Patients considering any peptide protocol should understand that the evidence base for combinations is weaker than for individual components, and that individual components themselves are not FDA-approved for the indications discussed.
The discussion below describes areas where the individual peptides in glow preparations have been investigated. None of these constitute approved indications. Treatment decisions for any specific condition belong with a prescribing physician.
BPC-157 has been studied in animal models of tendon and ligament repair. Patients with chronic tendinopathies (golfer's elbow, plantar fasciitis, rotator cuff issues, Achilles tendinopathy) that have not fully responded to conservative management sometimes inquire about peptide protocols. Clinical evidence in humans for these specific conditions remains limited to small case series and clinical observation.
Research on the individual peptides has investigated post-injury and post-surgical tissue healing. Any peptide protocol after surgery should be initiated only with the surgeon's knowledge, and typically not before acute bleeding risk has passed. That generally means a minimum of 2 weeks post-operative, depending on the procedure. Timing should be determined by the surgical and prescribing physicians, not by the patient.
GHK-Cu has the longest research history in dermatology of any peptide in this category. Topical GHK-Cu has been studied in cosmetic dermatology for decades. The injectable route reaches the dermis through a different mechanism than topical application. Patients in clinical observation often report dermal changes during the treatment window, though individual responses vary considerably.
BPC-157 has been investigated in animal models of NSAID-induced injury, inflammatory bowel models, and post-surgical gut healing. Human clinical trial data remains limited. Patients with active gastrointestinal symptoms should be evaluated for underlying causes before considering any peptide protocol.
TB-500 and GHK-Cu research touches on joint capsule and fascia. All three peptides have been investigated for effects on inflammatory signaling, though through different mechanisms. GHK-Cu has limited laboratory data on hair follicle stem cells. Controlled human trials for hair-related outcomes are sparse, and this should not be a primary reason to consider a peptide protocol.
Physician-directed dosing for a 10/10/50 glow preparation, reconstituted with 3 mL of bacteriostatic water, generally falls in the range of 10 to 15 units subcutaneously, once daily, for an initial period of approximately 4 weeks. Maintenance dosing after this period is individualized.
Actual dosing depends on body weight, the clinical reason for the protocol, prior peptide history, baseline labs, and how the patient responds in the first 2 weeks. Self-dosing based on internet protocols is not recommended. Without medical supervision, dose-response cannot be assessed, adverse effects may go unrecognized, and contraindications may be missed.
Subcutaneous injection is the most common route for these peptides. Absorption is reasonable and the technique carries lower risk than intramuscular injection. Intramuscular injection near a specific structure is sometimes used for targeted clinical indications, but the systemic effect of these peptides is generally similar across routes.
Common sites include the abdomen, outer thigh, and posterior upper arm. Site rotation reduces the risk of localized irritation. GHK-Cu solutions can be slightly more acidic than the other components, which may contribute to site tenderness if rotation is inconsistent.
Patient outcomes with any peptide protocol depend on multiple factors beyond the peptide itself. These factors are not failures on the patient's part. They are physiological inputs that affect any regenerative process.
Peptides are signaling molecules. They influence how tissues behave. They do not provide the raw materials the body needs to act on those signals. When underlying physiology is compromised, the response to any regenerative protocol is more limited.
This timeline reflects clinical observations from follow-up appointments at wellness clinics prescribing peptide protocols. It is not based on controlled clinical trials.
Limited human data: Only three small pilot studies have examined BPC-157 in humans. BPC-157 is not FDA-approved for injury recovery and is sold as a compounded preparation or research chemical.
Source: Natura Dermatology
Limitless Alternative Medicine prescribes compounded peptide preparations through licensed US pharmacies when clinically appropriate. The process includes baseline labs, individualized dosing, and structured follow-ups.
Schedule a Consultation →The same regenerative pathways that make these peptides of interest are also reasons certain patients should not use them. A prescribing physician will evaluate complete medical history before determining whether any peptide protocol is appropriate.
These contraindications are based on the peptides' mechanisms of action and theoretical risks from preclinical research. BPC-157, TB-500, and GHK-Cu are not FDA-approved for injury recovery or aesthetic use. Only three small pilot studies have examined BPC-157 in humans.
Common baseline labs include CBC, CMP, hsCRP, A1c, vitamin D, ferritin, and basic copper/zinc evaluation. Patients over 40 or with cardiovascular risk factors typically also have a lipid panel reviewed. Depending on personal and family history, additional screening (including tumor markers in certain cases) may be appropriate.
The decision to start, modify, or continue any peptide protocol is made by the prescribing physician based on the complete clinical picture.
This is not medical advice. Always consult your prescribing physician before starting peptide therapy.
The right option for any individual depends on clinical goals, medical history, and physician evaluation. No option in this table is FDA-approved as a finished drug product for the indications discussed in this article.
Compounded peptide preparations vary in cost depending on pharmacy, dose, prescribing physician, individual protocol, and shipping. Current pricing is provided during consultation, as cost depends on the specific preparation prescribed for an individual patient.
The distinction between the two pathways is regulatory and clinical, not promotional. Vendors selling research-grade peptides explicitly state their products are not for human use, and patients sourcing through that channel are assuming all clinical and quality risks.
Patients frequently ask about the difference between physician-prescribed compounded preparations and research-grade peptides available online. The honest answer is that they are different products under different regulatory frameworks, sold for different stated purposes.
Research peptide vendors sell lyophilized powders labeled "for laboratory and educational use only." This labeling is not marketing language. It reflects the vendor's legal position: the product was not manufactured to pharmaceutical standards, was not intended for human administration, and the vendor assumes no liability for human use.
Purity is not verified to pharmaceutical standards. Independent testing of research-grade peptide vials has found significant variation between labeled and actual content.
Sterility & endotoxin testing is often absent. A contaminated injection can produce a febrile reaction that mimics serious infection.
Cold chain is the buyer's responsibility. Heat exposure during shipping or storage can degrade the product.
Clinical oversight is absent. Adverse reactions, contraindications, and drug interactions are the user's problem to identify.
Legal status for human use is unsettled and varies by substance.
Patients who have used research-grade peptides without incident exist. Patients who have had adverse outcomes also exist. The decision to use any peptide outside of a physician-prescribed framework carries clinical, quality, and regulatory risk that the patient assumes entirely.
The process at Limitless Alternative Medicine follows the same structure used for the clinic's other peptide protocols. The intent is clinical thoroughness with a workable patient experience.
This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. BPC-157, TB-500, and GHK-Cu are not FDA-approved as finished drug products for the indications discussed in this article. Compounded preparations containing these peptides are prescribed by licensed physicians and dispensed by licensed pharmacies on an individual patient basis, where clinically appropriate and legally permissible.
The regulatory status of specific peptides changes over time. Current FDA guidance should be confirmed at the time of any treatment decision. Outcomes vary significantly between patients, and the information in this article should not be used to determine whether a peptide protocol is appropriate for any individual.
Do not begin, modify, or stop any medical treatment based on information in this article. Always consult a licensed medical provider regarding your individual health circumstances. Limitless Alternative Medicine does not endorse or facilitate the purchase of research-grade peptides for human administration.
If you experience any unexpected symptoms during a peptide protocol, contact your prescribing physician or, in case of emergency, seek immediate medical care.
Quick answers to the questions patients ask most often before their first consult.
No. The individual peptides are not FDA-approved as finished drug products for the uses discussed in this article. Compounded preparations are prescribed by licensed physicians and dispensed by licensed pharmacies under a different regulatory framework than branded FDA-approved drugs. Regulatory status of specific peptides can change over time.
Patient-reported timelines vary significantly. Some patients report subjective changes within 1 to 2 weeks. Visible or structural changes, when they occur, are more often reported between weeks 4 and 8. Some patients report little change. Outcomes are not guaranteed.
Most patients continue normal activity, with the prescribing physician's guidance on intensity. Maximal effort on a freshly injured structure is generally not advised. Specific recommendations depend on the clinical reason for the protocol and the patient's overall situation.
There is no established direct effect on body weight. Some patients report mild appetite changes during the first 2 weeks, often associated with gastrointestinal symptom changes rather than the peptides themselves.
Combination protocols require physician coordination. A prescribing physician will review all current medications during intake and assess for any concerns. Patients should not combine peptide protocols with other medications without physician oversight.
Oral BPC-157 capsules exist and have research interest for gastrointestinal applications, though clinical evidence remains limited. TB-500 and GHK-Cu have poor oral bioavailability based on available research, so the full three-peptide protocol does not translate to an oral form.
Refrigerated between 36 and 46°F, away from light. Reconstituted preparations are generally considered stable for 28 to 30 days when prepared with bacteriostatic water. Do not freeze. Storage instructions are provided with each prescription.
Patient-reported results tend to hold for several months after the washout period in patients who respond. Some patients pursue additional cycles 6 to 12 months out. Others discontinue. These decisions are made with the prescribing physician based on the clinical picture.
GHK-Cu has the longest human research history, primarily in dermatology, going back several decades. BPC-157 and TB-500 have extensive animal data and several years of clinical observation in regenerative medicine practice, but large-scale long-term human trials are limited. Patients considering any peptide protocol, particularly those considering longer-term use, should discuss this directly with their physician.
A single-peptide protocol uses one peptide for a specific clinical target. Glow preparations combine three peptides into one daily injection. The combination targets different mechanisms simultaneously. Whether the combination is preferable to a single peptide for any individual patient is a clinical decision based on goals, history, and physician evaluation.
A 30-minute televisit and a proper baseline panel tell you whether a peptide protocol makes sense for your situation. Or whether something else does.
Schedule a Televisit →